Gilead Sciences struck deals to acquire Sprint Bioscience’s preclinical TREX1‑targeted oncology program, paying upfront consideration to access the early‑stage asset and securing milestone‑based payouts that could reach roughly $400 million. Gilead has been building its oncology portfolio and views the TREX1 program as a strategic preclinical addition to its research pipeline. Sprint will advance other assets while receiving funds to support R&D. The transaction underscores big pharma’s continued appetite for early‑stage oncology intellectual property and the use of milestone structures to share risk for preclinical programs.